Ruth H Walton

US Patent:

7053104, May 30, 2006

Filed:

Aug 5, 2002

Appl. No.:

10/211523

Inventors:

Bradford C. Van Wagenen - Salt Lake City UT, US
Scott T. Moe - Ann Arbor MI, US
Daryl L. Smith - Fishers IN, US
Susan M. Sheehan - Dexter MI, US
Irina Shcherbakova - Salt Lake City UT, US
Ruth Walton - Bountiful UT, US
Richard Trovato - Salt Lake City UT, US
Robert Barmore - Salt Lake City UT, US
Eric G. Delmar - Salt Lake City UT, US
Thomas M. Stormann - Salt Lake City UT, US

Assignee:

NPS Pharmaceuticals, Inc. - Salt Lake City UT

International Classification:

A61K 31/47
C07D 215/14

US Classification:

514311, 546169, 546 90, 514291

Abstract:

The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

US Patent:

7678823, Mar 16, 2010

Filed:

Apr 4, 2007

Appl. No.:

11/696526

Inventors:

Rachel Slade - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Sandy UT, US
Mark B. Anderson - Salt Lake City UT, US
Kenton Zavitz - Salt Lake City UT, US

Assignee:

Myriad Pharmaceticals, Inc. - Salt Lake City UT

International Classification:

A61K 31/416
C07D 209/04

US Classification:

514412, 548516

Abstract:

The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH, -L-C(═O)NH(Calkyl), -L-C(═O)N(Calkyl), -L-S(═O)(Calkyl), -L-S(═O)NH, -L-S(═O)N(Calkyl), -L-S(═O)NH(Calkyl), -L-C(═O)NHOH, -L-C(═O)CHNH, -L-C(═O)CHOH, -L-C(═O)CHSH, -L-C(═O)NHCN, -L-NHC(═O)OR, -L-C(═O)NHR, -L-NH(C═O)NHR, -L-C(═O)N(R), -L-NH(C═O)N(R), -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.

US Patent:

7714022, May 11, 2010

Filed:

Mar 27, 2008

Appl. No.:

12/057140

Inventors:

Warren S. Weiner - Salt Lake City UT, US
Rachel M. Slade - Salt Lake City UT, US
Yevgeniya I. Klimova - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Mark B. Anderson - Salt Lake City UT, US

Assignee:

Myriad Pharmaceuticals, Inc. - Salt Lake City UT

International Classification:

A61K 31/40
C07D 207/30

US Classification:

514427, 548563

Abstract:

Novel pyrrole derivatives are disclosed as Aβ-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the Aβpeptide.

US Patent:

8217073, Jul 10, 2012

Filed:

May 6, 2010

Appl. No.:

12/775253

Inventors:

Warren S. Weiner - Salt Lake City UT, US
Rachel M. Slade - Salt Lake City UT, US
Yevgeniya I. Klimova - Sandy UT, US
Ruth J. Walton - Bountiful UT, US
Mark B. Anderson - Oakland CA, US

Assignee:

Myrexis, Inc. - Salt Lake City UT

International Classification:

A61K 31/40
C07D 207/30

US Classification:

514427, 548563

Abstract:

Novel pyrrole derivatives are disclosed as Aβ-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the Aβpeptide.

US Patent:

20100184975, Jul 22, 2010

Filed:

Mar 8, 2010

Appl. No.:

12/719672

Inventors:

Rachel Slade - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Salt Lake City UT, US
Mark B. Anderson - Oakland CA, US
Kenton Zavitz - Salt Lake City UT, US

Assignee:

Myriad Pharmaceuticals, Inc. - Salt Lake City UT

International Classification:

C07D 413/10
C07D 209/60
C07D 209/08
C07D 403/10
C07D 401/04
C07D 403/04

US Classification:

544143, 548427, 548516, 548254, 5462774, 544297

Abstract:

The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH, -L-C(═0)NH(Calkyl), -L-C(═O)N(Calkyl), -L-S(═O)(Calkyl), -L-S(═O)NH, -L-S(═O)N(Calkyl), -L-S(═O)NH(Calkyl), -L-C(═O)NHOH, -L-C(═O)CHNH, -L-C(═O)CHOH, -L-C(═O)CHSH, -L-C(═O)NHCN, -L-NHC(═O)OR, -L-C(═O)NHR, -L-NH(C═O)NHR, -L-C(═O)N(R), -L-NH(C═O)N(R), -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.

US Patent:

20120225873, Sep 6, 2012

Filed:

Apr 13, 2012

Appl. No.:

13/447115

Inventors:

Rachel Slade - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Salt Lake City UT, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Riverton UT, US
Mark B. Anderson - Orinda UT, US
Kenton Zavitz - Salt Lake City UT, US

Assignee:

Myrexis, Inc. - Salt Lake City UT

International Classification:

A61K 31/5377
A61K 31/4985
A61K 31/437
A61K 31/4439
C07D 413/14
A61K 31/422
A61K 31/403
C07D 403/10
C07D 209/18
C07D 413/10
A61K 31/501
C07D 471/06
C07D 401/04
C07D 417/04
C07D 413/04
C07D 491/10
C07D 209/90
A61K 31/404
C07D 209/12
C07D 413/08
C07D 401/14
C07D 405/14
A61P 25/28
A61K 31/5025

US Classification:

5142352, 514248, 514250, 51425201, 51425505, 514292, 514339, 514365, 514378, 514409, 514411, 514415, 514419, 544143, 544234, 544238, 544405, 546 84, 5462767, 5462774, 548214, 548247, 548254, 548411, 548427, 548509, 548510

Abstract:

The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimer's disease and dementia. The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH, -L-C(═O)NH(Calkyl), -L-C(═O)N(Calkyl), -L-S(═O)(Calkyl), -L-S(═O)NH, -L-S(═O)N(Calkyl), -L-S(═O)NH(Calkyl), -L-C(═O)NHOH, -L-C(═O)CHNH, -L-C(═O)CHOH, -L-C(═O)CHSH, -L-C(═O)NHCN, -L-NHC(═O)OR, -L-C(═O)NHR, -L-NH(C═O)NHR, -L-C(═O)N(R), -L-NH(C═O)N(R), -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.

US Patent:

20130261118, Oct 3, 2013

Filed:

Mar 13, 2013

Appl. No.:

13/801348

Inventors:

John Manfredi - , US
Christine Klein - Salt Lake City UT, US
Leena Bhoite - Salt Lake City UT, US
John Manfredi - Salt Lake City UT, US
Rachel M. Slade - Salt Lake City UT, US
Yevgeniya Klimova - Sandy UT, US
Robert J. Halter - Salt Lake City UT, US
Ashantai J. Yungai - Salt Lake City UT, US
Warren S. Weiner - Lawrence KS, US
Ruth J. Walton - Bountiful UT, US
Jon Adam Willardsen - Draper UT, US
Mark B. Anderson - Orinda CA, US
Kenton Zavitz - Salt Lake City UT, US

International Classification:

C07D 403/04
C07D 417/04
C07D 413/10
C07D 401/04
C07D 405/04

US Classification:

5142352, 5462774, 514339, 544331, 514275, 548465, 514414, 548194, 514370, 5482648, 514383

Abstract:

The present disclosure relates to novel indole and tetrahydroindole core compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport).

US Patent:

6429207, Aug 6, 2002

Filed:

May 19, 2000

Appl. No.:

09/573347

Inventors:

Bradford C. Van Wagenen - Salt Lake City UT
Scott T. Moe - Salt Lake City UT
Daryl L. Smith - Salt Lake City UT
Susan M. Sheehan - Dexter MI
Irina Shcherbakova - Salt Lake City UT
Richard Travato - Salt Lake City UT
Ruth Walton - Ogden UT
Robert Barmore - Salt Lake City UT
Eric G. Delmar - Salt Lake City UT
Thomas M. Stormann - Salt Lake City UT

Assignee:

NPS Pharmaceuticals, Inc. - Salt Lake City UT

International Classification:

A61K 31498

US Classification:

514249, 544355, 544354, 544353

Abstract:

The present invention provides compounds, and pharmaceutical compositions containing those compounds, that are active at metabotropic glutamate receptors. The compounds are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.